A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05949619
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05944978
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 584
- Registration Number
- NCT05943795
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05924841
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT05924750
- Locations
- 🇨🇳
Shanghai Tongji Hospital, Shanghai, Shanghai, China
🇨🇳West China Hospital，Sichuan University, Chengdu, Sichuan, China
🇨🇳Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 114
- Registration Number
- NCT05880706
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05803018
- Locations
- 🇨🇳
Fudan University ShangHai Cancer Center, Shanghai, Shanghai, China
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05785039
- Locations
- 🇨🇳
Fudan University ShangHai Cancer Center, Shanghai, Shanghai, China
Clinical Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05668858
- Locations
- 🇨🇳
Shanghai Oriental Hospital, Shanghai, Shanghai, China
Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT05631964
- Locations
- 🇨🇳
Fudan University ShangHai Cancer Center, Shanghai, Shanghai, China